Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Mar 21, 2019
Trial Information
Current as of April 26, 2025
Terminated
Keywords
ClinConnect Summary
In order to fully characterize the highly promising tracer In-111-DTPA-exendin-4 in humans, quantitative SPECT imaging will be correlated to the ex vivo tracer distribution in patients undergoing pancreatectomy or a Whipple procedure. In vivo imaging will be combined with post-pancreatectomy (micro)autoradiography, measurement of In-111-DTPA-exendin-4 concentrations in the pancreas using a gamma counter and morphometric determination of the actual beta cell mass. By this means, the relation between tracer uptake and beta cell mass in non-diabetic patients and T2D patients will be establishe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Scheduled for partial or complete pancreatectomy or Whipple procedure at Radboudumc
- Exclusion Criteria:
- • Resection that provides insufficient amount of tissue
- • Previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl- Peptidase IV inhibitors
- • Breast feeding
- • Pregnancy or the wish to become pregnant within 6 months
- • Renal disease
- • Liver disease
- • Age \< 18 years
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, Gelderland, Netherlands
Patients applied
Trial Officials
Martin Gotthardt, Prof. Dr.
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials